Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

with a strong clinical profile and as the only product approved for the treatment of [cold agglutinin disease], Enjaymo addresses a serious unmet medical need for patients living with this ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin ...

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...

The following column was originally published on May 1, 2021. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

Breathwork is a major part of any yoga practice as there are lots of different styles of pranayama that help with various things. Pranayama can be translated as controlling the life force, the ...

The Resolution Foundation data and research shows 7.7 MILLION households likely to struggle to heat homes this winter in a Cost of Living blow ... and Pensions (DWP) Cold Weather Payment scheme ...

If you tend to grab a sweater or blanket before others around you, you know what it’s like to always feel cold. And while all humans share a somewhat similar average body temperature ...

Also known as cold agglutinin disease (CAD), this type of hemolytic anemia is rarer. Overall, the symptoms of warm and cold hemolytic anemia are similar and largely the same as those of anemia ...